US Stock MarketDetailed Quotes

RPTX Repare Therapeutics

Watchlist

1.260
-0.030-2.33%

Close Feb 24 16:00 ET

53.56MMarket Cap-0.63P/E (TTM)

Repare Therapeutics Stock Forum

Lnova

Feb 16 00:27

Ark Investment 1,999,996 shares
has options
$Repare Therapeutics (RPTX.US)$
nfa

Repare Therapeutics | SCHEDULE 13G/A: Others

Jaguar8

Jan 10 06:16

NEWS

$Repare Therapeutics (RPTX.US)$
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
29 seconds ago, 4:15 AM PST
Via GlobeNewswire
RPRX
Share
• Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC
• Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6...

Jaguar8

Jan 9 15:25

NEWS

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Realigning resources to extend runway to mid-2027
Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025
Exploring partnerships for continued development of Lunre+Camo and other assets
January 09, 2025 04:05 PM Eastern Standard Time
CAMBRIDGE, Mass. & MONTREAL--...

WciStudios

Dec 13, 2024 13:26

$Repare Therapeutics (RPTX.US)$ lets crack 1.80 and at least hold

WciStudios

Dec 13, 2024 13:23

$Repare Therapeutics (RPTX.US)$

Trytosaveabit

Dec 13, 2024 08:03

Only posting this update because it validates what I said yesterday that results/data don’t justify the huge drop!

$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Reports Positive Data From MYTHIC Phase 1 Trial And Plans For Phase 3 In 2025
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...

Jaguar8

Dec 12, 2024 19:10

🕗Watchlist FRIDAY December 13. NFA. Tired now so I’ll attach the watchlist for Thursday and Wednesday and check those which didn’t run yet. Remember it’s our lucky day tomorrow: Friday 13th

NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...

Jaguar8

Dec 12, 2024 15:20

NEWS

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...

Jaguar8

Nov 12, 2024 06:05

NEWS

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...

Trytosaveabit

Oct 23, 2024 05:10

Update

$Repare Therapeutics (RPTX.US)$ Reuters· 4 mins ago
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial